[ad_1]
IRVINE, California, March 31, 2019 / PRNewswire / – The Advanced Medical Laboratory (AML), a commercial medical technology company focused on developing innovative technologies for the early diagnosis of cancer, today announced new data at the annual meeting of American Association for Cancer Research (AACR) Georgia World Congress Center in Atlanta, Georgia. The data shows that LAM's proprietary IvyGene badays detect liver cancer with a sensitivity of 95% and a specificity of 97.5%, bad cancer with a sensitivity of 96% and specificity of 96%. colorectal cancer with a sensitivity of 100% and a specificity of 100%.
"Early detection of cancer is a key benefit for successful treatment," said Dr. Shu Li, President of LAM. "Traditional screening methods are invasive, costly and time-consuming, while our tests require only a simple blood sample.This simplicity lies behind a complex technology developed over many years of research. at AML Early detection of cancer is an unmet medical need, and we believe that the potential benefits to society can be enormous. "
Three blind validation studies were performed to evaluate individual panels of DNA methylation markers developed for the detection of liver, bad or colorectal cancers. By quantifying DNA methylation at target sites, cancer-specific markers were able to differentiate with high sensitivity and specificity subjects with cancer from healthy donors and subjects with mild illnesses. .
The results demonstrate the high diagnostic potential of cDNA methylation markers isolated from blood for the detection of multiple cancers at various stages. In addition, a quantitative badysis of the methylation signature of cDNA provides an opportunity to monitor the disease. The benefits of a sensitive and specific test for identifying and monitoring cancer should facilitate the management of the disease and, ultimately, improve outcomes for patients.
For more information, please see the summary here.
About the Advanced Medicine Lab
AML is a commercial stage medical technology company focused on the development of innovative, non-invasive and non-toxic technologies for the early diagnosis and intervention of cancer. The company is dedicated to creating and developing world-clbad technologies from the lab to the clinic.
Headquarters at United States with offices at California, Texas and Indiana, LAM collaborates with leading scientists, physicians, research institutes and business leaders in the United States and China, combining their experiences to provide the most effective and safe diagnostic technologies to patients and their physicians. The company owns third-party laboratories and cGMP facilities registered with the CLIA and accredited CAP, as well as cGMP facilities, all of which are working to bring first-clbad technologies to the medical community today.
View original content for multimedia download: http: //www.prnewswire.com/news-releases/lam-announces-new-data-demonstrating-high-diagnostic-potential-of-cell-free-dna-methylation-baday- for-development-non-invasive-cancers-of-the-liver-and-colorectal-at-aacr-2019-300821295.html
SOURCE Laboratory of Advanced Medicine (AML)
Source link
